Kisqali was approved for the new indication on the back of the NATALEE trial, in which adding Kisqali to standard treatment ...

The plan – backed with a £2 billion ($2.68 billion) funding pledge – revolves around three overarching objectives; namely, ...

EVERSANA has launched a new pharmacovigilance (PV) platform that answers the need to apply advanced data analytics and ...

Draft guidance from reimbursement authority NICE has recommended use of the artificial intelligence technologies – Aidoc ...

Just over two years into Anderson's tenure, Bayer's board has decided to extend his contract by three years to 31st March ...

With the rise of advanced simulation and model-informed drug development (MIDD) techniques like digital twins, researchers ...

Developing new biomarker assays is highly specialised work. It requires careful screening of antibody pairs, sensitivity and ...

At ASCO 2025, Johnson & Johnson contributed more than 70 abstracts, reflecting the depth of their oncology portfolio, and commitment to redefining what’s possible for a wide range of solid tumour and ...

From dissecting clinical updates to identifying novel targets beyond NLRP3, this summit brings together the brightest minds transforming the field of innate immunity and inflammation.

Healthinote is a smartphone-based toolkit designed to boost patient engagement by providing personalised, trustworthy, and ...

By 2023, the tone had shifted. Venture capital cooled. According to CB Insights, funding for AI drug discovery start-ups ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...